With one drug in the market, one will summit NDA in weeks, one started phase 3 right after they got money from financing, 4 in phase 2, 1 in phase 1 and many in preclinical, AEZS worth at least 100 million!!!
I have never seen a biotech company significantly undervalued like this.
"Following the successfull Phase 3 trial results in AGHD, for which orphan-drug status had been granted by the FDA in 2007, the Company expects to file a new drug application (NDA) in 2Q-2013"
Simply wait for couple weeks, I believe the market will wake up when the NDA news come out.
This company is not worth the money shareholders have already lost. The NDA will more than likely never be filed, they have had two years to do so. It makes no difference how many drugs are in the pipe line before they are approved this company will have diluted the shareholders to death. You can not believe anything they say. I have held this company since 2010 and have seen them do all they can to screw shareholders.